Smith & Nephew 관리

관리 기준 확인 3/4

Smith & Nephew CEO는 Deepak Nath, Apr2022 에 임명되었습니다 의 임기는 2.67 년입니다. 총 연간 보상은 $ 4.66M, 32.5% 로 구성됩니다. 32.5% 급여 및 67.5% 보너스(회사 주식 및 옵션 포함). 는 $ 1.98M 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 1.98M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 2.8 년입니다.

주요 정보

Deepak Nath

최고 경영자

US$4.7m

총 보상

CEO 급여 비율	32.5%
CEO 임기	2.7yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Deepak Nath 의 보수는 Smith & Nephew 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 29 2024	n/a	n/a	US$305m
Mar 29 2024	n/a	n/a	US$284m
Dec 31 2023	US$5m	US$2m	US$263m
Sep 30 2023	n/a	n/a	US$241m
Jul 01 2023	n/a	n/a	US$218m
Apr 01 2023	n/a	n/a	US$221m
Dec 31 2022	US$6m	US$1m	US$223m

보상 대 시장: Deepak 의 총 보상 ($USD 4.66M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 12.84M ).

보상과 수익: Deepak 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Deepak Nath (52 yo)

2.7yrs

테뉴어

US$4,658,252

보상

Dr. Deepak S. Nath, Ph D., serves as Director at Smith & Nephew plc since April 1, 2022. He served as Head of Diagnostics at Siemens Healthineers AG since 2021 until 2022 and served as its President of Lab...

리더십 팀

이름	위치	테뉴어	보상	소유권
Deepak Nath	CEO & Director	2.7yrs	US$4.66m	0.018% $ 2.0m
John Rogers	CFO & Executive Director	less than a year	데이터 없음	데이터 없음
Paul Connolly	President of Global Operations	3.2yrs	데이터 없음	0.0019% $ 201.3k
Andrew Swift	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Helen Barraclough	Group General Counsel & Company Secretary	2.9yrs	데이터 없음	0.0040% $ 430.6k
Alison Parkes	Chief Compliance Officer & Compliance APAC	2.9yrs	데이터 없음	0.00025% $ 26.9k
Joe Metzger	Senior Vice President of Marketing Services & Communications	13.9yrs	데이터 없음	데이터 없음
Philip Cowdy	Chief Corporate Development & Corporate Affairs Officer	no data	데이터 없음	0.0066% $ 714.8k
Elga Lohler	Chief Human Resources Officer	9yrs	데이터 없음	0.019% $ 2.0m
Vasant Padmanabhan	President of Research & Development and Ear	8.3yrs	데이터 없음	0.014% $ 1.5m
Steve Kane	Head of Human Resources for the US	no data	데이터 없음	데이터 없음
Ian Melling	Senior Vice President of Group Finance	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SNNU.F 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Deepak Nath	CEO & Director	2.7yrs	US$4.66m	0.018% $ 2.0m
John Rogers	CFO & Executive Director	less than a year	데이터 없음	데이터 없음
Marc Owen	Independent Director	7.2yrs	US$206.78k	0.0020% $ 213.1k
Simon Lowth	Independent Non-Executive Director	less than a year	데이터 없음	0.000030% $ 3.2k
Rupert Soames	Independent Non-Executive Chairman	1.7yrs	US$180.82k	0.0023% $ 244.4k
Angela Risley	Senior Independent Director	7.3yrs	US$118.56k	0.00069% $ 74.3k
Changzheng Ma	Independent Non-Executive Director	3.8yrs	US$171.78k	0.00028% $ 30.1k
Jeremy Maiden	Independent Non-Executive Director	1.3yrs	US$26.24k	0.00015% $ 16.1k
Katarzyna Mazur-Hofsaess	Independent Non-Executive Director	4.1yrs	US$93.06k	0.00021% $ 22.6k
Joanna Hallas	Independent Non-Executive Director	2.8yrs	US$93.06k	0.00071% $ 76.4k
Robert White	Independent Non-Executive Director	4.6yrs	US$164.78k	0.00093% $ 100.1k

2.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: SNNU.F 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/27 08:36
장 마감 주가	2024/12/23 00:00
수익	2024/06/29
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Smith & Nephew plc 57 애널리스트 중 18 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Kamla Singh	AlphaValue
Christoph Gubler	Bank Vontobel AG
Hassan Al-Wakeel	Barclays

Smith & Nephew 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Recent updates

Smith+Nephew Introduces CORIOGRAPH Pre-Op Planning and Modeling Services for Total Hip Arthroplasty

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew plc Announces Appointment of John Ma as Non-Executive Director, Effective 17 February 2021

Smith+Nephew Partners with Movemedical to Streamline Inventory Management and Improve Customer Experience

Smith & Nephew plc Confirms Retirement of Vinita Bali as Non-Executive Director

Smith & Nephew plc (LSE:SN.) completed the acquisition of Extremity Orthopedics business of Integra LifeSciences Holdings Corporation.

Smith+Nephew Announces Outstanding Clinical Results for Its Total Hip Arthroplasty Portfolio

Smith & Nephew plc to Report Q2, 2021 Results on Jul 29, 2021

Smith+Nephew Adds Patient Selection and Care-Pathway Optimization Tools to ARIA Digital Care Management Platform for ASCs

Smith & Nephew plc to Report Fiscal Year 2020 Results on Feb 18, 2021

Smith & Nephew plc (LSE:SN.) agreed to acquire Extremity Orthopedics business of Integra LifeSciences Holdings Corporation for $240 million.

Smith & Nephew Plc agreed to acquire Plus Orthopedics Holding AG from Invision AG and others for $889 million.

Smith & Nephew plc Announces the Company Is Not Providing Updated 2020 Guidance